Healthcare Utilization and Costs Associated with Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide 1 Receptor Agonists or Sodium-Glucose Cotransporter 2 Inhibitors

Newman T, Munshi KD, Neilson LM, Good CB, Swart ECS, Huang Y, Henderson R, Parekh N. Healthcare Utilization and Costs Associated with Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide 1 Receptor Agonists or Sodium-Glucose Cotransporter 2 Inhibitors. J Manag Care and Spec Pharm, 2021;27(4):435-443. https://www.jmcp.org/doi/pdf/10.18553/jmcp.2021.27.4.435